Latest Pharma Insights
Dove Courts US Open Fans, Degree Hits NYC Subway With Summer Campaigns
Unilever is running simultaneous summer campaigns for its Dove and Degree deodorant brands, targeting US Open tennis fans and New York City subway commuters.
HBW Insight - August 13, 2026
Unilever is running simultaneous summer campaigns for its Dove and Degree deodorant brands, targeting US Open tennis fans and New York City subway commuters.
HBW Insight - August 13, 2026
US FDA ‘Simple Reform’ Reorg Approved; Inspection ‘Generalist’ Changes Coming Later
Reorganization will move HR, IT and other shared services into one office will take effect later this year, but changes to the ‘generalist’ inspection approach were not included.
HBW Insight - August 13, 2026
Reorganization will move HR, IT and other shared services into one office will take effect later this year, but changes to the ‘generalist’ inspection approach were not included.
HBW Insight - August 13, 2026
Taiho, Cullinan To Submit Zipalertinib For Second Claim While First Pending
Taiho and Cullinan announced positive topline results from the Phase III REZILIENT3 trial of zipalertinib in first-line NSCLC with EGFR exon 20 insertion mutations.
Scrip - August 13, 2026
Taiho and Cullinan announced positive topline results from the Phase III REZILIENT3 trial of zipalertinib in first-line NSCLC with EGFR exon 20 insertion mutations.
Scrip - August 13, 2026
Khartis Founders Raise $95m To Take Another Shot At Oral Immunology Drugs
Funding Snapshot: Khartis Therapeutics has raised $95m, including a $50m series B round. Its founders previously sold oral cancer and immunology drug developer XinThera to Gilead.
Scrip - August 13, 2026
Funding Snapshot: Khartis Therapeutics has raised $95m, including a $50m series B round. Its founders previously sold oral cancer and immunology drug developer XinThera to Gilead.
Scrip - August 13, 2026
Execs On The Move: August 3–7, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - August 13, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - August 13, 2026
Remediation At Major Production Facility Puts Spotlight On One-Third of Amphastar Sales
Amphastar braces for higher costs and some sales pressure as it remediates a production facility, while newer generics support growth and it keeps its insulin aspart biosimilar on track for potential 2027 launch.
HBW Insight - August 13, 2026
Amphastar braces for higher costs and some sales pressure as it remediates a production facility, while newer generics support growth and it keeps its insulin aspart biosimilar on track for potential 2027 launch.
HBW Insight - August 13, 2026
The Protocol Is The Problem – And The Answer Lies In Its Digital Twin
AI-powered simulation is moving clinical trial design from historical precedent to predictive engineering. The implications for sponsors and CROs are significant.
In Vivo - August 13, 2026
AI-powered simulation is moving clinical trial design from historical precedent to predictive engineering. The implications for sponsors and CROs are significant.
In Vivo - August 13, 2026
Abbott And Google Partner To Bring Lingo Glucose Data Into Google Health App
Abbott and Google announced a multi-year partnership to integrate Abbott’s Lingo continuous glucose sensor into the Google Health app, pairing CGM data with AI-driven insights to help people better understand their metabolic health.
Medtech Insight - August 13, 2026
Abbott and Google announced a multi-year partnership to integrate Abbott’s Lingo continuous glucose sensor into the Google Health app, pairing CGM data with AI-driven insights to help people better understand their metabolic health.
Medtech Insight - August 13, 2026
The Self-Care Confidence Gap: Pharmacists Struggle Most Where Industry Is Growing Fastest
An Opella-funded FIP survey shows pharmacists' confidence in advising consumers is highest for mature categories like pain and fever and lowest in liver health, sleep, weight management and other areas where OTC companies are growing fastest.
HBW Insight - August 13, 2026
An Opella-funded FIP survey shows pharmacists' confidence in advising consumers is highest for mature categories like pain and fever and lowest in liver health, sleep, weight management and other areas where OTC companies are growing fastest.
HBW Insight - August 13, 2026
MHRA Quarantines 6 Uncertified Medical Devices
Products used in healthcare settings including blood infusion, biopsies and wound management entered the UK market by unknown means.
Medtech Insight - August 13, 2026
Products used in healthcare settings including blood infusion, biopsies and wound management entered the UK market by unknown means.
Medtech Insight - August 13, 2026
Trump’s MMR Split Puts US Vaccine Makers In Commercial Limbo
Trump’s push to replace combination vaccination with individual shots could now test whether manufacturers see enough certainty to invest in a new product mix.
Scrip - August 13, 2026
Trump’s push to replace combination vaccination with individual shots could now test whether manufacturers see enough certainty to invest in a new product mix.
Scrip - August 13, 2026
Sangamo’s Bankruptcy Sale Splits Gene Therapy Assets Between Lilly, PTC
A distressed auction handed PTC Therapeutics a Fabry therapy months from filing and Eli Lilly several gene-editing and delivery platforms.
Scrip - August 13, 2026
A distressed auction handed PTC Therapeutics a Fabry therapy months from filing and Eli Lilly several gene-editing and delivery platforms.
Scrip - August 13, 2026
Low Demand Causes TÜV NORD Scandinavia Bankruptcy Just 7 Months After Purchase
Swedish notified body will shut its doors after a financial review found that disproportionate investment would be required to make it profitable.
Medtech Insight - August 13, 2026
Swedish notified body will shut its doors after a financial review found that disproportionate investment would be required to make it profitable.
Medtech Insight - August 13, 2026
BioVie Maps Out Parkinson’s Phase III After Endpoint Row And Stock Rout
BioVie is advancing bezisterim into a Parkinson's Phase III trial after an endpoint controversy wiped more than half its market value following the Phase II readout.
Scrip - August 13, 2026
BioVie is advancing bezisterim into a Parkinson's Phase III trial after an endpoint controversy wiped more than half its market value following the Phase II readout.
Scrip - August 13, 2026
Vykat Safety Concerns Take Shine Off Neurocrine Soleno Buy
Seven deaths and other adverse events associated with use of the Prader Willi syndrome drug have led to calls for more caution over its use, but a rival’s Phase III failure has left it more in command the market.
Scrip - August 13, 2026
Seven deaths and other adverse events associated with use of the Prader Willi syndrome drug have led to calls for more caution over its use, but a rival’s Phase III failure has left it more in command the market.
Scrip - August 13, 2026
Zealand Cashes In On Rusfertide With Royalty Pact
Deal Snapshot: The Danish drugmaker is selling its economic interests in the blood cancer drug to Royalty for $100m to focus on its core metabolic health business.
Scrip - August 13, 2026
Deal Snapshot: The Danish drugmaker is selling its economic interests in the blood cancer drug to Royalty for $100m to focus on its core metabolic health business.
Scrip - August 13, 2026
Aeon Buys Time For Botox Biosimilar As Key FDA Feedback Looms
Aeon has extended its cash runway into 2027 and regained NYSE American compliance as it awaits FDA feedback that will shape the clinical requirements for its proposed Botox biosimilar ABP-450.
Generics Bulletin - August 13, 2026
Aeon has extended its cash runway into 2027 and regained NYSE American compliance as it awaits FDA feedback that will shape the clinical requirements for its proposed Botox biosimilar ABP-450.
Generics Bulletin - August 13, 2026
Mabwell Secures Global Deals For Eylea Biosimilar
Mabwell has secured four new commercialization deals for its aflibercept biosimilar across the GCC and ASEAN regions, while its wholly owned subsidiary T-mab passed a second PIC/S GMP inspection for its denosumab biosimilars.
Generics Bulletin - August 13, 2026
Mabwell has secured four new commercialization deals for its aflibercept biosimilar across the GCC and ASEAN regions, while its wholly owned subsidiary T-mab passed a second PIC/S GMP inspection for its denosumab biosimilars.
Generics Bulletin - August 13, 2026
Industry Groups Urge India To Enact Standalone Medical Devices Act, Say 30-Plus Fixes Ignored
Eleven Indian industry and patient groups have written to the health minister demanding a standalone Medical Devices Act, saying the 2026 draft bill recycles rejected proposals and applies pharma-style criminalization to engineering products.
Medtech Insight - August 13, 2026
Eleven Indian industry and patient groups have written to the health minister demanding a standalone Medical Devices Act, saying the 2026 draft bill recycles rejected proposals and applies pharma-style criminalization to engineering products.
Medtech Insight - August 13, 2026
Five Barriers Blocking Asia-Pacific’s Medtech Ascent — And The Playbooks To Overcome Them
Regulatory approval is only the beginning. Reimbursement, talent, IP, funding and infrastructure gaps are preventing Asia-Pacific medtechs from scaling globally. Here’s what founders, MNCs and governments must do differently.
Medtech Insight - August 13, 2026
Regulatory approval is only the beginning. Reimbursement, talent, IP, funding and infrastructure gaps are preventing Asia-Pacific medtechs from scaling globally. Here’s what founders, MNCs and governments must do differently.
Medtech Insight - August 13, 2026
ANI Targets 15-Plus Annual Generics Launches To Sustain Rare Disease Push
ANI’s generics business kept growing and accelerated its launch cadence in Q2, reinforcing its role as a cash generator for the company’s rare disease expansion even as Cortrophin guidance was trimmed.
Generics Bulletin - August 13, 2026
ANI’s generics business kept growing and accelerated its launch cadence in Q2, reinforcing its role as a cash generator for the company’s rare disease expansion even as Cortrophin guidance was trimmed.
Generics Bulletin - August 13, 2026
ICH Finalizes Guideline To Harmonize Additional-Strength Biowaivers
ICH’s finalized M13B guideline sets a harmonized pathway for additional-strength biowaivers, with industry welcoming the potential to reduce duplicative bioequivalence studies while clarifying formulation and dissolution requirements.
Generics Bulletin - August 13, 2026
ICH’s finalized M13B guideline sets a harmonized pathway for additional-strength biowaivers, with industry welcoming the potential to reduce duplicative bioequivalence studies while clarifying formulation and dissolution requirements.
Generics Bulletin - August 13, 2026
Landmark FDA Clearance Moves Aurisco Closer To Leqvio Supply
Aurisco has cleared an FDA pre-approval inspection for inclisiran sodium at its Yangzhou site, strengthening its position as a US-facing supplier of generic oligonucleotide APIs while also advancing a broader complex API and finished-dose strategy.
Generics Bulletin - August 13, 2026
Aurisco has cleared an FDA pre-approval inspection for inclisiran sodium at its Yangzhou site, strengthening its position as a US-facing supplier of generic oligonucleotide APIs while also advancing a broader complex API and finished-dose strategy.
Generics Bulletin - August 13, 2026
Chinese AI-Driven Biotechs Make Splash With Financing Deals, Again
AI-powered Chinese ventures Phil Rivers and Beyang raise around $30m apiece in their latest funding rounds backed by venture capital and private equity firms.
Scrip - August 13, 2026
AI-powered Chinese ventures Phil Rivers and Beyang raise around $30m apiece in their latest funding rounds backed by venture capital and private equity firms.
Scrip - August 13, 2026
Taiho, Cullinan To Submit Zipalertinib For Second Claim While First Pending
Taiho and Cullinan announced positive topline results from the Phase III REZILIENT3 trial of zipalertinib in first-line NSCLC with EGFR exon 20 insertion mutations.
Scrip - August 13, 2026
Taiho and Cullinan announced positive topline results from the Phase III REZILIENT3 trial of zipalertinib in first-line NSCLC with EGFR exon 20 insertion mutations.
Scrip - August 13, 2026
Khartis Founders Raise $95m To Take Another Shot At Oral Immunology Drugs
Funding Snapshot: Khartis Therapeutics has raised $95m, including a $50m series B round. Its founders previously sold oral cancer and immunology drug developer XinThera to Gilead.
Scrip - August 13, 2026
Funding Snapshot: Khartis Therapeutics has raised $95m, including a $50m series B round. Its founders previously sold oral cancer and immunology drug developer XinThera to Gilead.
Scrip - August 13, 2026
Trump’s MMR Split Puts US Vaccine Makers In Commercial Limbo
Trump’s push to replace combination vaccination with individual shots could now test whether manufacturers see enough certainty to invest in a new product mix.
Scrip - August 13, 2026
Trump’s push to replace combination vaccination with individual shots could now test whether manufacturers see enough certainty to invest in a new product mix.
Scrip - August 13, 2026
Sangamo’s Bankruptcy Sale Splits Gene Therapy Assets Between Lilly, PTC
A distressed auction handed PTC Therapeutics a Fabry therapy months from filing and Eli Lilly several gene-editing and delivery platforms.
Scrip - August 13, 2026
A distressed auction handed PTC Therapeutics a Fabry therapy months from filing and Eli Lilly several gene-editing and delivery platforms.
Scrip - August 13, 2026
BioVie Maps Out Parkinson’s Phase III After Endpoint Row And Stock Rout
BioVie is advancing bezisterim into a Parkinson's Phase III trial after an endpoint controversy wiped more than half its market value following the Phase II readout.
Scrip - August 13, 2026
BioVie is advancing bezisterim into a Parkinson's Phase III trial after an endpoint controversy wiped more than half its market value following the Phase II readout.
Scrip - August 13, 2026
Vykat Safety Concerns Take Shine Off Neurocrine Soleno Buy
Seven deaths and other adverse events associated with use of the Prader Willi syndrome drug have led to calls for more caution over its use, but a rival’s Phase III failure has left it more in command the market.
Scrip - August 13, 2026
Seven deaths and other adverse events associated with use of the Prader Willi syndrome drug have led to calls for more caution over its use, but a rival’s Phase III failure has left it more in command the market.
Scrip - August 13, 2026
Zealand Cashes In On Rusfertide With Royalty Pact
Deal Snapshot: The Danish drugmaker is selling its economic interests in the blood cancer drug to Royalty for $100m to focus on its core metabolic health business.
Scrip - August 13, 2026
Deal Snapshot: The Danish drugmaker is selling its economic interests in the blood cancer drug to Royalty for $100m to focus on its core metabolic health business.
Scrip - August 13, 2026
Chinese AI-Driven Biotechs Make Splash With Financing Deals, Again
AI-powered Chinese ventures Phil Rivers and Beyang raise around $30m apiece in their latest funding rounds backed by venture capital and private equity firms.
Scrip - August 13, 2026
AI-powered Chinese ventures Phil Rivers and Beyang raise around $30m apiece in their latest funding rounds backed by venture capital and private equity firms.
Scrip - August 13, 2026
Execs On The Move: August 3–7, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - August 13, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - August 13, 2026
Abbott And Google Partner To Bring Lingo Glucose Data Into Google Health App
Abbott and Google announced a multi-year partnership to integrate Abbott’s Lingo continuous glucose sensor into the Google Health app, pairing CGM data with AI-driven insights to help people better understand their metabolic health.
Medtech Insight - August 13, 2026
Abbott and Google announced a multi-year partnership to integrate Abbott’s Lingo continuous glucose sensor into the Google Health app, pairing CGM data with AI-driven insights to help people better understand their metabolic health.
Medtech Insight - August 13, 2026
MHRA Quarantines 6 Uncertified Medical Devices
Products used in healthcare settings including blood infusion, biopsies and wound management entered the UK market by unknown means.
Medtech Insight - August 13, 2026
Products used in healthcare settings including blood infusion, biopsies and wound management entered the UK market by unknown means.
Medtech Insight - August 13, 2026
Low Demand Causes TÜV NORD Scandinavia Bankruptcy Just 7 Months After Purchase
Swedish notified body will shut its doors after a financial review found that disproportionate investment would be required to make it profitable.
Medtech Insight - August 13, 2026
Swedish notified body will shut its doors after a financial review found that disproportionate investment would be required to make it profitable.
Medtech Insight - August 13, 2026
Industry Groups Urge India To Enact Standalone Medical Devices Act, Say 30-Plus Fixes Ignored
Eleven Indian industry and patient groups have written to the health minister demanding a standalone Medical Devices Act, saying the 2026 draft bill recycles rejected proposals and applies pharma-style criminalization to engineering products.
Medtech Insight - August 13, 2026
Eleven Indian industry and patient groups have written to the health minister demanding a standalone Medical Devices Act, saying the 2026 draft bill recycles rejected proposals and applies pharma-style criminalization to engineering products.
Medtech Insight - August 13, 2026
Five Barriers Blocking Asia-Pacific’s Medtech Ascent — And The Playbooks To Overcome Them
Regulatory approval is only the beginning. Reimbursement, talent, IP, funding and infrastructure gaps are preventing Asia-Pacific medtechs from scaling globally. Here’s what founders, MNCs and governments must do differently.
Medtech Insight - August 13, 2026
Regulatory approval is only the beginning. Reimbursement, talent, IP, funding and infrastructure gaps are preventing Asia-Pacific medtechs from scaling globally. Here’s what founders, MNCs and governments must do differently.
Medtech Insight - August 13, 2026
Dove Courts US Open Fans, Degree Hits NYC Subway With Summer Campaigns
Unilever is running simultaneous summer campaigns for its Dove and Degree deodorant brands, targeting US Open tennis fans and New York City subway commuters.
HBW Insight - August 13, 2026
Unilever is running simultaneous summer campaigns for its Dove and Degree deodorant brands, targeting US Open tennis fans and New York City subway commuters.
HBW Insight - August 13, 2026
US FDA ‘Simple Reform’ Reorg Approved; Inspection ‘Generalist’ Changes Coming Later
Reorganization will move HR, IT and other shared services into one office will take effect later this year, but changes to the ‘generalist’ inspection approach were not included.
HBW Insight - August 13, 2026
Reorganization will move HR, IT and other shared services into one office will take effect later this year, but changes to the ‘generalist’ inspection approach were not included.
HBW Insight - August 13, 2026
Remediation At Major Production Facility Puts Spotlight On One-Third of Amphastar Sales
Amphastar braces for higher costs and some sales pressure as it remediates a production facility, while newer generics support growth and it keeps its insulin aspart biosimilar on track for potential 2027 launch.
HBW Insight - August 13, 2026
Amphastar braces for higher costs and some sales pressure as it remediates a production facility, while newer generics support growth and it keeps its insulin aspart biosimilar on track for potential 2027 launch.
HBW Insight - August 13, 2026
The Self-Care Confidence Gap: Pharmacists Struggle Most Where Industry Is Growing Fastest
An Opella-funded FIP survey shows pharmacists' confidence in advising consumers is highest for mature categories like pain and fever and lowest in liver health, sleep, weight management and other areas where OTC companies are growing fastest.
HBW Insight - August 13, 2026
An Opella-funded FIP survey shows pharmacists' confidence in advising consumers is highest for mature categories like pain and fever and lowest in liver health, sleep, weight management and other areas where OTC companies are growing fastest.
HBW Insight - August 13, 2026
Aeon Buys Time For Botox Biosimilar As Key FDA Feedback Looms
Aeon has extended its cash runway into 2027 and regained NYSE American compliance as it awaits FDA feedback that will shape the clinical requirements for its proposed Botox biosimilar ABP-450.
Generics Bulletin - August 13, 2026
Aeon has extended its cash runway into 2027 and regained NYSE American compliance as it awaits FDA feedback that will shape the clinical requirements for its proposed Botox biosimilar ABP-450.
Generics Bulletin - August 13, 2026
Mabwell Secures Global Deals For Eylea Biosimilar
Mabwell has secured four new commercialization deals for its aflibercept biosimilar across the GCC and ASEAN regions, while its wholly owned subsidiary T-mab passed a second PIC/S GMP inspection for its denosumab biosimilars.
Generics Bulletin - August 13, 2026
Mabwell has secured four new commercialization deals for its aflibercept biosimilar across the GCC and ASEAN regions, while its wholly owned subsidiary T-mab passed a second PIC/S GMP inspection for its denosumab biosimilars.
Generics Bulletin - August 13, 2026
ANI Targets 15-Plus Annual Generics Launches To Sustain Rare Disease Push
ANI’s generics business kept growing and accelerated its launch cadence in Q2, reinforcing its role as a cash generator for the company’s rare disease expansion even as Cortrophin guidance was trimmed.
Generics Bulletin - August 13, 2026
ANI’s generics business kept growing and accelerated its launch cadence in Q2, reinforcing its role as a cash generator for the company’s rare disease expansion even as Cortrophin guidance was trimmed.
Generics Bulletin - August 13, 2026
ICH Finalizes Guideline To Harmonize Additional-Strength Biowaivers
ICH’s finalized M13B guideline sets a harmonized pathway for additional-strength biowaivers, with industry welcoming the potential to reduce duplicative bioequivalence studies while clarifying formulation and dissolution requirements.
Generics Bulletin - August 13, 2026
ICH’s finalized M13B guideline sets a harmonized pathway for additional-strength biowaivers, with industry welcoming the potential to reduce duplicative bioequivalence studies while clarifying formulation and dissolution requirements.
Generics Bulletin - August 13, 2026
Landmark FDA Clearance Moves Aurisco Closer To Leqvio Supply
Aurisco has cleared an FDA pre-approval inspection for inclisiran sodium at its Yangzhou site, strengthening its position as a US-facing supplier of generic oligonucleotide APIs while also advancing a broader complex API and finished-dose strategy.
Generics Bulletin - August 13, 2026
Aurisco has cleared an FDA pre-approval inspection for inclisiran sodium at its Yangzhou site, strengthening its position as a US-facing supplier of generic oligonucleotide APIs while also advancing a broader complex API and finished-dose strategy.
Generics Bulletin - August 13, 2026
The Protocol Is The Problem – And The Answer Lies In Its Digital Twin
AI-powered simulation is moving clinical trial design from historical precedent to predictive engineering. The implications for sponsors and CROs are significant.
In Vivo - August 13, 2026
AI-powered simulation is moving clinical trial design from historical precedent to predictive engineering. The implications for sponsors and CROs are significant.
In Vivo - August 13, 2026